Access to the next wave of biologic therapies (Abatacept and Tocilizumab) for the treatment of rheumatoid arthritis in England and Wales: Addressing treatment outside the current NICE guidance

Patients in England and Wales with rheumatoid arthritis (RA) receive treatment from the National Health Service (NHS) with therapies approved by the European Medicines Agency (EMA), under guidance from the National Institute for Health and Clinical Excellence (NICE). This document overviews the curr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical rheumatology 2012-06, Vol.31 (6), p.1005-1012
Hauptverfasser: Chiu, Yee, Ostor, Andrew J. K., Hammond, Anthony, Sokoll, Katharina, Anderson, Marina, Buch, Maya, Ehrenstein, Michael R., Gordon, Patrick, Steer, Sophia, Bruce, Ian N.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1012
container_issue 6
container_start_page 1005
container_title Clinical rheumatology
container_volume 31
creator Chiu, Yee
Ostor, Andrew J. K.
Hammond, Anthony
Sokoll, Katharina
Anderson, Marina
Buch, Maya
Ehrenstein, Michael R.
Gordon, Patrick
Steer, Sophia
Bruce, Ian N.
description Patients in England and Wales with rheumatoid arthritis (RA) receive treatment from the National Health Service (NHS) with therapies approved by the European Medicines Agency (EMA), under guidance from the National Institute for Health and Clinical Excellence (NICE). This document overviews the current NICE guidelines for the treatment of RA and identifies scenarios when such guidance may not represent the optimum management strategy for individual patients. Specifically, we consider the use of tocilizumab or abatacept as the most appropriate treatments for some patients. In such scenarios, it may be possible for the clinician to secure access to the required therapy through an application procedure known as an ‘individual funding request’, the process of which is described in detail here. At present, it is unclear the extent to which the proposed reform of the NHS will affect the role of NICE in providing guidance and setting standards of care. Until the full impact of the proposed changes are realized, individual funding requests will remain a valuable way of securing the optimal treatment for all patients suffering from RA.
doi_str_mv 10.1007/s10067-011-1936-6
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3362712</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1017986636</sourcerecordid><originalsourceid>FETCH-LOGICAL-c379t-6dce40000216180c339b977d4ade3f4fa7fa6627920766103335554ff75d38383</originalsourceid><addsrcrecordid>eNp1kc1uFSEcxYnR2Gv1AdwYEjftYpSPuTBsTG6aVk2auKlxSRjmP_fSzMAVmPrxBD620FubamIIsDiHHxwOQi8peUMJkW9TWYVsCKUNVVw04hFa0Za3jVKteoxWRErScKq6I_QspWtCCOsUfYqOGGOSMqZW6NfGWkgJ54DzDrCH7xl_MzeAw4h7F6awdbYq0ewdJHyy6U02FvYZGz_gq2Dd5H4us-lP8RjiLSNHMHkGnysj7qCoObgBm5h30WWXsPP43G-nSqjzi5kgPUdPRjMleHG3H6PPF-dXZx-ay0_vP55tLhvLpcqNGCy0pCahgnbEcq56JeXQmgH42I5GjkYIJhUjUghKOOfr9bodR7keeFfGMXp34O6XfoZC8zmaSe-jm038oYNx-m_Fu53ehhvNuaifVgAnd4AYvi6Qsp5dsjCVOBCWpCmhUnVCcFGsr_-xXocl-hLv1iVIx0R10YPLxpBShPH-MZTo2rM-9KxLz7r2rOuZVw9T3J_4U2wxsIMhFclvIT68-n_U3zJLs6A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1017608266</pqid></control><display><type>article</type><title>Access to the next wave of biologic therapies (Abatacept and Tocilizumab) for the treatment of rheumatoid arthritis in England and Wales: Addressing treatment outside the current NICE guidance</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Chiu, Yee ; Ostor, Andrew J. K. ; Hammond, Anthony ; Sokoll, Katharina ; Anderson, Marina ; Buch, Maya ; Ehrenstein, Michael R. ; Gordon, Patrick ; Steer, Sophia ; Bruce, Ian N.</creator><creatorcontrib>Chiu, Yee ; Ostor, Andrew J. K. ; Hammond, Anthony ; Sokoll, Katharina ; Anderson, Marina ; Buch, Maya ; Ehrenstein, Michael R. ; Gordon, Patrick ; Steer, Sophia ; Bruce, Ian N.</creatorcontrib><description>Patients in England and Wales with rheumatoid arthritis (RA) receive treatment from the National Health Service (NHS) with therapies approved by the European Medicines Agency (EMA), under guidance from the National Institute for Health and Clinical Excellence (NICE). This document overviews the current NICE guidelines for the treatment of RA and identifies scenarios when such guidance may not represent the optimum management strategy for individual patients. Specifically, we consider the use of tocilizumab or abatacept as the most appropriate treatments for some patients. In such scenarios, it may be possible for the clinician to secure access to the required therapy through an application procedure known as an ‘individual funding request’, the process of which is described in detail here. At present, it is unclear the extent to which the proposed reform of the NHS will affect the role of NICE in providing guidance and setting standards of care. Until the full impact of the proposed changes are realized, individual funding requests will remain a valuable way of securing the optimal treatment for all patients suffering from RA.</description><identifier>ISSN: 0770-3198</identifier><identifier>ISSN: 1434-9949</identifier><identifier>EISSN: 1434-9949</identifier><identifier>DOI: 10.1007/s10067-011-1936-6</identifier><identifier>PMID: 22271229</identifier><language>eng</language><publisher>London: Springer-Verlag</publisher><subject>Abatacept ; Antibodies, Monoclonal, Humanized - therapeutic use ; Antirheumatic Agents - therapeutic use ; Arthritis, Rheumatoid - therapy ; Brief Report ; Cost-Benefit Analysis ; Decision Making ; England ; Guidelines as Topic ; Health Care Costs ; Health Services Accessibility ; Humans ; Immunoconjugates - therapeutic use ; Medicine ; Medicine &amp; Public Health ; National Health Programs ; Outcome Assessment, Health Care ; Rheumatology ; Rheumatology - methods ; Treatment Outcome ; Wales</subject><ispartof>Clinical rheumatology, 2012-06, Vol.31 (6), p.1005-1012</ispartof><rights>The Author(s) 2012</rights><rights>Clinical Rheumatology 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c379t-6dce40000216180c339b977d4ade3f4fa7fa6627920766103335554ff75d38383</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10067-011-1936-6$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10067-011-1936-6$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22271229$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chiu, Yee</creatorcontrib><creatorcontrib>Ostor, Andrew J. K.</creatorcontrib><creatorcontrib>Hammond, Anthony</creatorcontrib><creatorcontrib>Sokoll, Katharina</creatorcontrib><creatorcontrib>Anderson, Marina</creatorcontrib><creatorcontrib>Buch, Maya</creatorcontrib><creatorcontrib>Ehrenstein, Michael R.</creatorcontrib><creatorcontrib>Gordon, Patrick</creatorcontrib><creatorcontrib>Steer, Sophia</creatorcontrib><creatorcontrib>Bruce, Ian N.</creatorcontrib><title>Access to the next wave of biologic therapies (Abatacept and Tocilizumab) for the treatment of rheumatoid arthritis in England and Wales: Addressing treatment outside the current NICE guidance</title><title>Clinical rheumatology</title><addtitle>Clin Rheumatol</addtitle><addtitle>Clin Rheumatol</addtitle><description>Patients in England and Wales with rheumatoid arthritis (RA) receive treatment from the National Health Service (NHS) with therapies approved by the European Medicines Agency (EMA), under guidance from the National Institute for Health and Clinical Excellence (NICE). This document overviews the current NICE guidelines for the treatment of RA and identifies scenarios when such guidance may not represent the optimum management strategy for individual patients. Specifically, we consider the use of tocilizumab or abatacept as the most appropriate treatments for some patients. In such scenarios, it may be possible for the clinician to secure access to the required therapy through an application procedure known as an ‘individual funding request’, the process of which is described in detail here. At present, it is unclear the extent to which the proposed reform of the NHS will affect the role of NICE in providing guidance and setting standards of care. Until the full impact of the proposed changes are realized, individual funding requests will remain a valuable way of securing the optimal treatment for all patients suffering from RA.</description><subject>Abatacept</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Antirheumatic Agents - therapeutic use</subject><subject>Arthritis, Rheumatoid - therapy</subject><subject>Brief Report</subject><subject>Cost-Benefit Analysis</subject><subject>Decision Making</subject><subject>England</subject><subject>Guidelines as Topic</subject><subject>Health Care Costs</subject><subject>Health Services Accessibility</subject><subject>Humans</subject><subject>Immunoconjugates - therapeutic use</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>National Health Programs</subject><subject>Outcome Assessment, Health Care</subject><subject>Rheumatology</subject><subject>Rheumatology - methods</subject><subject>Treatment Outcome</subject><subject>Wales</subject><issn>0770-3198</issn><issn>1434-9949</issn><issn>1434-9949</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kc1uFSEcxYnR2Gv1AdwYEjftYpSPuTBsTG6aVk2auKlxSRjmP_fSzMAVmPrxBD620FubamIIsDiHHxwOQi8peUMJkW9TWYVsCKUNVVw04hFa0Za3jVKteoxWRErScKq6I_QspWtCCOsUfYqOGGOSMqZW6NfGWkgJ54DzDrCH7xl_MzeAw4h7F6awdbYq0ewdJHyy6U02FvYZGz_gq2Dd5H4us-lP8RjiLSNHMHkGnysj7qCoObgBm5h30WWXsPP43G-nSqjzi5kgPUdPRjMleHG3H6PPF-dXZx-ay0_vP55tLhvLpcqNGCy0pCahgnbEcq56JeXQmgH42I5GjkYIJhUjUghKOOfr9bodR7keeFfGMXp34O6XfoZC8zmaSe-jm038oYNx-m_Fu53ehhvNuaifVgAnd4AYvi6Qsp5dsjCVOBCWpCmhUnVCcFGsr_-xXocl-hLv1iVIx0R10YPLxpBShPH-MZTo2rM-9KxLz7r2rOuZVw9T3J_4U2wxsIMhFclvIT68-n_U3zJLs6A</recordid><startdate>20120601</startdate><enddate>20120601</enddate><creator>Chiu, Yee</creator><creator>Ostor, Andrew J. K.</creator><creator>Hammond, Anthony</creator><creator>Sokoll, Katharina</creator><creator>Anderson, Marina</creator><creator>Buch, Maya</creator><creator>Ehrenstein, Michael R.</creator><creator>Gordon, Patrick</creator><creator>Steer, Sophia</creator><creator>Bruce, Ian N.</creator><general>Springer-Verlag</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20120601</creationdate><title>Access to the next wave of biologic therapies (Abatacept and Tocilizumab) for the treatment of rheumatoid arthritis in England and Wales</title><author>Chiu, Yee ; Ostor, Andrew J. K. ; Hammond, Anthony ; Sokoll, Katharina ; Anderson, Marina ; Buch, Maya ; Ehrenstein, Michael R. ; Gordon, Patrick ; Steer, Sophia ; Bruce, Ian N.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c379t-6dce40000216180c339b977d4ade3f4fa7fa6627920766103335554ff75d38383</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Abatacept</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Antirheumatic Agents - therapeutic use</topic><topic>Arthritis, Rheumatoid - therapy</topic><topic>Brief Report</topic><topic>Cost-Benefit Analysis</topic><topic>Decision Making</topic><topic>England</topic><topic>Guidelines as Topic</topic><topic>Health Care Costs</topic><topic>Health Services Accessibility</topic><topic>Humans</topic><topic>Immunoconjugates - therapeutic use</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>National Health Programs</topic><topic>Outcome Assessment, Health Care</topic><topic>Rheumatology</topic><topic>Rheumatology - methods</topic><topic>Treatment Outcome</topic><topic>Wales</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chiu, Yee</creatorcontrib><creatorcontrib>Ostor, Andrew J. K.</creatorcontrib><creatorcontrib>Hammond, Anthony</creatorcontrib><creatorcontrib>Sokoll, Katharina</creatorcontrib><creatorcontrib>Anderson, Marina</creatorcontrib><creatorcontrib>Buch, Maya</creatorcontrib><creatorcontrib>Ehrenstein, Michael R.</creatorcontrib><creatorcontrib>Gordon, Patrick</creatorcontrib><creatorcontrib>Steer, Sophia</creatorcontrib><creatorcontrib>Bruce, Ian N.</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chiu, Yee</au><au>Ostor, Andrew J. K.</au><au>Hammond, Anthony</au><au>Sokoll, Katharina</au><au>Anderson, Marina</au><au>Buch, Maya</au><au>Ehrenstein, Michael R.</au><au>Gordon, Patrick</au><au>Steer, Sophia</au><au>Bruce, Ian N.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Access to the next wave of biologic therapies (Abatacept and Tocilizumab) for the treatment of rheumatoid arthritis in England and Wales: Addressing treatment outside the current NICE guidance</atitle><jtitle>Clinical rheumatology</jtitle><stitle>Clin Rheumatol</stitle><addtitle>Clin Rheumatol</addtitle><date>2012-06-01</date><risdate>2012</risdate><volume>31</volume><issue>6</issue><spage>1005</spage><epage>1012</epage><pages>1005-1012</pages><issn>0770-3198</issn><issn>1434-9949</issn><eissn>1434-9949</eissn><abstract>Patients in England and Wales with rheumatoid arthritis (RA) receive treatment from the National Health Service (NHS) with therapies approved by the European Medicines Agency (EMA), under guidance from the National Institute for Health and Clinical Excellence (NICE). This document overviews the current NICE guidelines for the treatment of RA and identifies scenarios when such guidance may not represent the optimum management strategy for individual patients. Specifically, we consider the use of tocilizumab or abatacept as the most appropriate treatments for some patients. In such scenarios, it may be possible for the clinician to secure access to the required therapy through an application procedure known as an ‘individual funding request’, the process of which is described in detail here. At present, it is unclear the extent to which the proposed reform of the NHS will affect the role of NICE in providing guidance and setting standards of care. Until the full impact of the proposed changes are realized, individual funding requests will remain a valuable way of securing the optimal treatment for all patients suffering from RA.</abstract><cop>London</cop><pub>Springer-Verlag</pub><pmid>22271229</pmid><doi>10.1007/s10067-011-1936-6</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0770-3198
ispartof Clinical rheumatology, 2012-06, Vol.31 (6), p.1005-1012
issn 0770-3198
1434-9949
1434-9949
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3362712
source MEDLINE; SpringerNature Journals
subjects Abatacept
Antibodies, Monoclonal, Humanized - therapeutic use
Antirheumatic Agents - therapeutic use
Arthritis, Rheumatoid - therapy
Brief Report
Cost-Benefit Analysis
Decision Making
England
Guidelines as Topic
Health Care Costs
Health Services Accessibility
Humans
Immunoconjugates - therapeutic use
Medicine
Medicine & Public Health
National Health Programs
Outcome Assessment, Health Care
Rheumatology
Rheumatology - methods
Treatment Outcome
Wales
title Access to the next wave of biologic therapies (Abatacept and Tocilizumab) for the treatment of rheumatoid arthritis in England and Wales: Addressing treatment outside the current NICE guidance
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T16%3A50%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Access%20to%20the%20next%20wave%20of%20biologic%20therapies%20(Abatacept%20and%20Tocilizumab)%20for%20the%20treatment%20of%20rheumatoid%20arthritis%20in%20England%20and%20Wales:%20Addressing%20treatment%20outside%20the%20current%20NICE%20guidance&rft.jtitle=Clinical%20rheumatology&rft.au=Chiu,%20Yee&rft.date=2012-06-01&rft.volume=31&rft.issue=6&rft.spage=1005&rft.epage=1012&rft.pages=1005-1012&rft.issn=0770-3198&rft.eissn=1434-9949&rft_id=info:doi/10.1007/s10067-011-1936-6&rft_dat=%3Cproquest_pubme%3E1017986636%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1017608266&rft_id=info:pmid/22271229&rfr_iscdi=true